The following table disaggregates our product sales by product and geographic region and disaggregates our royalty, contract and other revenues by geographic region for the three and six months ended June 30, 2018 and 2017. The information for the three and six months ended June 30, 2017 has not been adjusted in accordance with our modified retrospective adoption of Topic 606 and continues to be reported in accordance with our historical accounting under Topic 605.



	Three Months Ended June 30, 2018								Three Months Ended June 30, 2017
(In millions)	U.S.		Europe		Other International		Total		U.S.		Europe		Other International		Total
Product sales:
Atripla	$	274	$	39	$	36	$	349	$	334	$	86	$	55	$	475
Biktarvy	183		2		—		185		—		—		—		—
Complera/Eviplera	82		103		14		199		112		127		15		254
Descovy	311		78		14		403		232		47		7		286
Genvoya	904		207		49		1,160		710		125		22		857
Odefsey	303		77		5		385		230		27		1		258
Stribild	144		34		9		187		225		54		14		293
Truvada	649		86		30		765		567		184		61		812
Other HIV⁽¹⁾	11		3		5		19		7		2		2		11
Revenue share - Symtuza⁽²⁾	—		13		—		13		—		—		—		—
AmBisome	14		55		34		103		8		50		34		92
Epclusa	239		168		93		500		864		248		59		1,171
Harvoni	230		22		79		331		984		230		168		1,382
Letairis	244		—		—		244		230		—		—		230
Ranexa	208		—		—		208		200		—		—		200
Vemlidy	59		3		14		76		21		1		—		22
Viread	16		32		34		82		141		76		83		300
Vosevi	86		20		3		109		—		—		—		—
Yescarta	68		—		—		68		—		—		—		—
Zydelig	17		22		—		39		19		16		—		35
Other⁽³⁾	27		41		47		115		98		126		144		368
Total product sales	4,069		1,005		466		5,540		4,982		1,399		665		7,046
Royalty, contract and other revenues	14		79		15		108		22		59		14		95
Total revenues	$	4,083	$	1,084	$	481	$	5,648	$	5,004	$	1,458	$	679	$	7,141



	Six Months Ended June 30, 2018								Six Months Ended June 30, 2017
(In millions)	U.S.		Europe		Other International		Total		U.S.		Europe		Other International		Total
Product Sales:
Atripla	$	502	$	90	$	71	$	663	$	650	$	180	$	97	$	927
Biktarvy	218		2		—		220		—		—		—		—
Complera/Eviplera	149		212		28		389		224		252		31		507
Descovy	585		153		26		764		441		84		12		537
Genvoya	1,757		393		92		2,242		1,379		212		35		1,626
Odefsey	582		135		10		727		433		50		2		485
Stribild	277		63		21		361		451		121		30		602
Truvada	1,156		183		78		1,417		1,031		373		122		1,526
Other HIV⁽¹⁾	20		4		8		32		21		3		2		26
Revenue share - Symtuza⁽²⁾	—		20		—		20		—		—		—		—
AmBisome	31		111		68		210		17		102		65		184
Epclusa	508		366		162		1,036		1,599		386		78		2,063
Harvoni	464		78		137		679		1,910		473		370		2,753
Letairis	448		—		—		448		441		—		—		441
Ranexa	403		—		—		403		353		—		—		353
Vemlidy	106		6		22		134		32		1		—		33
Viread	23		62		94		179		258		147		155		560
Vosevi	172		36		8		216		—		—		—		—
Yescarta	108		—		—		108		—		—		—		—
Zydelig	31		40		1		72		34		35		1		70
Other⁽³⁾	56		56		109		221		158		246		326		730
Total product sales	7,596		2,010		935		10,541		9,432		2,665		1,326		13,423
Royalty, contract and other revenues	34		131		30		195		41		152		30		223
Total revenues	$	7,630	$	2,141	$	965	$	10,736	$	9,473	$	2,817	$	1,356	$	13,646

____________________
⁽¹⁾ Includes Emtriva and Tybost
⁽²⁾Represents Gilead’s revenue from cobicistat (C), emtricitabine (FTC) and tenofovir alafenamide (TAF) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen
⁽³⁾ Includes Cayston, Hepsera and Sovaldi